China National Medicines' falling ROCE and high dependence on short-term creditors could worry potential investors. The modest 32% stock gain over five years may reflect these concerns. The firm's reinvestment despite declining returns may not bode well for multi-bagger investors.

China National Medicines' reinvestment of capital hasn't significantly boosted sales and may take more time to positively impact earnings. Its declining ROCE and high liabilities make it an unlikely multi-bagger, suggesting investors look elsewhere.